PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH ...
Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III ...
Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast ...
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib in treating metastatic ...
The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
At this time, we expect that the COVID-19 pandemic will have limited impact on our clinical development program, as this crisis struck at a time when most of our on-going clinical studies were ...
AB Science announced in March 2023 a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results